Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Erin Hawkins

Nurse Practitioner, Family Bridgeport, WV Nurse Practitioner

NPI 1073500773 CMS profile 11123014

120 Medical Park Dr, Suite 300, Bridgeport, WV 26330

Open in the dashboard

General payments

$9,012

494 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Erin Hawkins of Bridgeport, WV is reported in the CMS Open Payments database as having received $9,012 across 494 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,722 87
2024 General $1,598 91
2023 General $1,538 97
2022 General $2,443 121
2021 General $1,712 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Erin Hawkins
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Erin Hawkins were reported at $1,722. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Erin Hawkins Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,712 $124 $35–$379 $132
2022 $2,443 $141 $44–$430 $149
2023 $1,538 $154 $49–$476 $160
2024 $1,598 $165 $51–$504 $164
2025 $1,722 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,671 108 payments
  2. Novo Nordisk Inc $1,500 72 payments
  3. Astellas Pharma US Inc $1,063 53 payments
  4. Amgen Inc. $741 49 payments
  5. Pfizer Inc. $491 30 payments
  6. AstraZeneca Pharmaceuticals LP $487 17 payments
  7. Janssen Pharmaceuticals, Inc $417 7 payments
  8. Lilly USA, LLC $279 13 payments
  9. Novartis Pharmaceuticals Corporation $242 18 payments
  10. Exact Sciences Corporation $231 15 payments
  11. Other $1,890 112 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,779 491 payments
  2. Education $233 3 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,068 51 payments
  2. RYBELSUS $992 49 payments
  3. UBRELVY $730 36 payments
  4. Veozah $528 28 payments
  5. QULIPTA $429 23 payments
  6. Otezla $397 33 payments
  7. BREZTRI $366 9 payments
  8. XARELTO $358 6 payments
  9. EVENITY $315 14 payments
  10. LINZESS $312 33 payments
  11. Other $6,311 382 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 156 drugs

Part D claims

8,499

Median for Nurse Practitioner: 389

Drug cost

$992,818

Median for Nurse Practitioner: $21,885

Branded share of claims

22.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 154 $214,168
Eliquis Apixaban Brand 133 $104,969
Mounjaro Tirzepatide Brand 65 $76,109
Trulicity Dulaglutide Brand 52 $51,494
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 53 $45,976
Repatha Sureclick Evolocumab Brand 63 $44,396
Januvia Sitagliptin Phosphate Brand 31 $42,626
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 47 $36,444
Xarelto Rivaroxaban Brand 39 $33,099
Linzess Linaclotide Brand 38 $31,005

The 10 drugs with the highest cost, of 156 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$57,523

Of which drugs: $5,859

Medicare patients

171

Average age 73

Services billed

3,540

128 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 37%
Chronic kidney disease 26%
COPD 25%
Depression 25%
Osteoporosis 23%
Ischemic heart disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 38 38 $3,109
Injection, methylprednisolone acetate, 1 mg J1010 Office 18 2,160 $217
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 64 $25
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 23 $8

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $150
$150 — —
JARDIANCE
  • Lilly USA, LLC $115
$115 16 —
RYBELSUS
  • Novo Nordisk Inc $114
$114 — —
Ozempic
  • Novo Nordisk Inc $114
$114 154 —
UBRELVY
  • AbbVie, Inc. $89
$89 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

494 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record